Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.

Duits LC, Lao-Sirieix P, Wolf WA, O'Donovan M, Galeano-Dalmau N, Meijer SL, Offerhaus GJA, Redman J, Crawte J, Zeki S, Pouw RE, Chak A, Shaheen NJ, Bergman JJGHM, Fitzgerald RC.

Dis Esophagus. 2019 Jan 1;32(1). doi: 10.1093/dote/doy102.

PMID:
30496496
2.

Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.

Offman J, Muldrew B, O'Donovan M, Debiram-Beecham I, Pesola F, Kaimi I, Smith SG, Wilson A, Khan Z, Lao-Sirieix P, Aigret B, Walter FM, Rubin G, Morris S, Jackson C, Sasieni P, Fitzgerald RC; BEST3 Trial team.

BMC Cancer. 2018 Aug 3;18(1):784. doi: 10.1186/s12885-018-4664-3.

3.

Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus.

Li X, Kleeman S, Coburn SB, Fumagalli C, Perner J, Jammula S, Pfeiffer RM, Orzolek L, Hao H, Taylor PR, Miremadi A, Galeano-Dalmau N, Lao-Sirieix P, Tennyson M, MacRae S, Cook MB, Fitzgerald RC.

Gastroenterology. 2018 Sep;155(3):771-783.e3. doi: 10.1053/j.gastro.2018.05.050. Epub 2018 Jun 12.

4.

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, Reid NB, Spence VJ, Chisambo C, McManus D, James J, McQuaid S, Craig S, Arthur K, McArt D, Ong CJ, Lao-Sirieix P, Hamilton P, Salto-Tellez M, Eatock M, Coleman HG, Fitzgerald RC, Kennedy RD, Turkington RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Oncotarget. 2018 Apr 6;9(26):18518-18528. doi: 10.18632/oncotarget.24906. eCollection 2018 Apr 6.

5.

Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.

Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, Fessas P, Walker E, Varghese S, Evan T, Lao-Sirieix PS, O'Donovan M, Malhotra S, Novelli M, Disep B, Kaye PV, Lovat LB, Haidry R, Griffin M, Ragunath K, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Ostler R, Aigret B, Sasieni PD, Fitzgerald RC; BEST2 study group.

Lancet Gastroenterol Hepatol. 2017 Jan;2(1):23-31. doi: 10.1016/S2468-1253(16)30118-2. Epub 2016 Nov 11. Erratum in: Lancet Gastroenterol Hepatol. 2017 Jul;2(7):e4.

PMID:
28404010
6.

Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms.

Paterson AL, Lao-Sirieix P, O'Donovan M, Debiram-Beecham I, di Pietro M, Miremadi A, Attwood SE, Walter FM, Sasieni PD, Fitzgerald RC; BEST and BEST2 study groups.

Histopathology. 2017 Jan;70(2):203-210. doi: 10.1111/his.13039. Epub 2016 Oct 12.

PMID:
27417524
7.

The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma.

Couch G, Redman JE, Wernisch L, Newton R, Malhotra S, Dawsey SM, Lao-Sirieix P, Fitzgerald RC.

Cancer Prev Res (Phila). 2016 Jul;9(7):558-66. doi: 10.1158/1940-6207.CAPR-15-0379. Epub 2016 Apr 12.

8.

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.

De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H.

Br J Cancer. 2015 Nov 3;113(9):1305-12. doi: 10.1038/bjc.2015.342. Epub 2015 Oct 20.

9.

Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.

Varghese S, Newton R, Ross-Innes CS, Lao-Sirieix P, Krishnadath KK, O'Donovan M, Novelli M, Wernisch L, Bergman J, Fitzgerald RC.

Gastroenterology. 2015 Nov;149(6):1511-1518.e5. doi: 10.1053/j.gastro.2015.07.053. Epub 2015 Aug 3.

PMID:
26248086
10.

Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.

Ross-Innes CS, Debiram-Beecham I, O'Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, Sami SS, Kaye P, Novelli M, Disep B, Ostler R, Aigret B, North BV, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Sasieni PD, Fitzgerald RC; BEST2 Study Group.

PLoS Med. 2015 Jan 29;12(1):e1001780. doi: 10.1371/journal.pmed.1001780. eCollection 2015 Jan.

11.

Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran.

Roshandel G, Merat S, Sotoudeh M, Khoshnia M, Poustchi H, Lao-Sirieix P, Malhotra S, O'Donovan M, Etemadi A, Nickmanesh A, Pourshams A, Norouzi A, Debiram I, Semnani S, Abnet CC, Dawsey SM, Fitzgerald RC, Malekzadeh R.

Br J Cancer. 2014 Dec 9;111(12):2235-41. doi: 10.1038/bjc.2014.506. Epub 2014 Sep 23.

12.

Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis.

Katzka DA, Geno DM, Ravi A, Smyrk TC, Lao-Sirieix P, Miremadi A, Debiram I, O'Donovan M, Kita H, Kephart GM, Kryzer LA, Camilleri M, Alexander JA, Fitzgerald RC.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):77-83.e2. doi: 10.1016/j.cgh.2014.06.026. Epub 2014 Jul 3. Erratum in: Clin Gastroenterol Hepatol. 2015 Aug;13(8):1552. Miramedi, Ahmed [corrected to Miremadi, Ahmed].

PMID:
24997328
13.

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CJ, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O'Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PAW, Rosenfeld N, Tavaré S, Fitzgerald RC; OCCAMS consortium.

Nat Genet. 2014 Aug;46(8):837-843. doi: 10.1038/ng.3013. Epub 2014 Jun 22.

14.

Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus.

Liu X, Wong A, Kadri SR, Corovic A, O'Donovan M, Lao-Sirieix P, Lovat LB, Burnham RW, Fitzgerald RC.

PLoS One. 2014 Apr 15;9(4):e94163. doi: 10.1371/journal.pone.0094163. eCollection 2014.

15.

The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus.

di Pietro M, Boerwinkel DF, Shariff MK, Liu X, Telakis E, Lao-Sirieix P, Walker E, Couch G, Mills L, Nuckcheddy-Grant T, Slininger S, O'Donovan M, Visser M, Meijer SL, Kaye PV, Wernisch L, Ragunath K, Bergman JJ, Fitzgerald RC.

Gut. 2015 Jan;64(1):49-56. doi: 10.1136/gutjnl-2013-305975. Epub 2014 Apr 10.

16.

A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus.

Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, Lao-Sirieix P, Gammon MD, Corley DA, Shaheen NJ, Bird NC, Hardie LJ, Murray LJ, Reid BJ, Chow WH, Risch HA, Nyrén O, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Chanock SJ, Harrington P, Caldas I, Debiram-Beecham I, Caldas C, Hayward NK, Pharoah PD, Fitzgerald RC, Macgregor S, Whiteman DC, Vaughan TL.

Nat Genet. 2013 Dec;45(12):1487-93. doi: 10.1038/ng.2796. Epub 2013 Oct 13.

17.

Endoscopic TriModal imaging and biomarkers for neoplasia conjoined: a feasibility study in Barrett's esophagus.

Boerwinkel DF, Di Pietro M, Liu X, Shariff MK, Lao-Sirieix P, Walker CE, Visser M, O' Donovan M, Kaye P, Bergman JJ, Fitzgerald RC.

Dis Esophagus. 2014 Jul;27(5):435-43. doi: 10.1111/j.1442-2050.2012.01428.x. Epub 2012 Oct 15.

PMID:
23067399
18.

A systematic approach to therapeutic target selection in oesophago-gastric cancer.

Paterson AL, Shannon NB, Lao-Sirieix P, Ong CA, Peters CJ, O'Donovan M, Fitzgerald RC.

Gut. 2013 Oct;62(10):1415-24. doi: 10.1136/gutjnl-2012-302039. Epub 2012 Jul 6.

19.

Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.

Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, Johnston BT, Arthur K, McManus DT, Novelli MR, O'Donovan M, Cardwell CR, Lovat LB, Murray LJ, Fitzgerald RC.

Gastroenterology. 2012 Oct;143(4):927-35.e3. doi: 10.1053/j.gastro.2012.06.041. Epub 2012 Jul 3.

PMID:
22771507
20.

Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus.

di Pietro M, Lao-Sirieix P, Boyle S, Cassidy A, Castillo D, Saadi A, Eskeland R, Fitzgerald RC.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9077-82. doi: 10.1073/pnas.1116933109. Epub 2012 May 17.

21.

Screening for oesophageal cancer.

Lao-Sirieix P, Fitzgerald RC.

Nat Rev Clin Oncol. 2012 Mar 20;9(5):278-87. doi: 10.1038/nrclinonc.2012.35. Review.

PMID:
22430857
22.

Identification and clinical implementation of biomarkers for Barrett's esophagus.

Varghese S, Lao-Sirieix P, Fitzgerald RC.

Gastroenterology. 2012 Mar;142(3):435-441.e2. doi: 10.1053/j.gastro.2012.01.013. Epub 2012 Jan 20. Review. No abstract available.

PMID:
22266150
23.

Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus.

Bird-Lieberman EL, Neves AA, Lao-Sirieix P, O'Donovan M, Novelli M, Lovat LB, Eng WS, Mahal LK, Brindle KM, Fitzgerald RC.

Nat Med. 2012 Jan 15;18(2):315-21. doi: 10.1038/nm.2616.

PMID:
22245781
24.

Developing a nonendoscopic screening test for Barrett's esophagus.

Kadri S, Lao-Sirieix P, Fitzgerald RC.

Biomark Med. 2011 Jun;5(3):397-404. doi: 10.2217/bmm.11.40. Review.

PMID:
21657849
25.

Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

Ong CA, Lao-Sirieix P, Fitzgerald RC.

World J Gastroenterol. 2010 Dec 7;16(45):5669-81. Review.

26.

Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study.

Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM, Pharoah P, Hardwick RH, Fitzgerald RC.

BMJ. 2010 Sep 10;341:c4372. doi: 10.1136/bmj.c4372.

27.

Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma.

Clemons NJ, Shannon NB, Abeyratne LR, Walker CE, Saadi A, O'Donovan ML, Lao-Sirieix PP, Fitzgerald RC.

Carcinogenesis. 2010 Sep;31(9):1669-75. doi: 10.1093/carcin/bgq130. Epub 2010 Jun 27.

PMID:
20584750
28.

Genetic predisposition to gastro-oesophageal cancer.

Lao-Sirieix P, Caldas C, Fitzgerald RC.

Curr Opin Genet Dev. 2010 Jun;20(3):210-7. doi: 10.1016/j.gde.2010.03.002. Epub 2010 Mar 26. Review.

PMID:
20347291
29.

Role of the micro-environment in Barrett's carcinogenesis.

Lao-Sirieix P, Fitzgerald RC.

Biochem Soc Trans. 2010 Apr;38(2):327-30. doi: 10.1042/BST0380327. Review.

PMID:
20298177
30.

Treatment for Barrett's oesophagus.

Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004060. doi: 10.1002/14651858.CD004060.pub2. Review.

PMID:
20091557
31.

Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.

Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2177-82. doi: 10.1073/pnas.0909797107. Epub 2010 Jan 13.

32.

Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic.

Lao-Sirieix P, Boussioutas A, Kadri SR, O'Donovan M, Debiram I, Das M, Harihar L, Fitzgerald RC.

Gut. 2009 Nov;58(11):1451-9. doi: 10.1136/gut.2009.180281. Epub 2009 Aug 2.

PMID:
19651633
33.

The definition and management of Barrett's oesophagus: a case report, review of the literature and a suggestion for the future.

Bird-Lieberman EL, Lao-Sirieix P, Saeed I, Khoo D, Burnham R, Fitzgerald R.

BMJ Case Rep. 2009;2009. pii: bcr07.2008.0450. doi: 10.1136/bcr.07.2008.0450. Epub 2009 Jun 1.

34.

Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus.

Lao-Sirieix P, Corovic A, Jankowski J, Lowe A, Triadafilopoulos G, Fitzgerald RC.

Dis Esophagus. 2008;21(6):529-38. doi: 10.1111/j.1442-2050.2007.00807.x.

PMID:
18840137
35.

Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk.

Barber ME, Save V, Carneiro F, Dwerryhouse S, Lao-Sirieix P, Hardwick RH, Caldas C, Fitzgerald RC.

J Pathol. 2008 Nov;216(3):286-94. doi: 10.1002/path.2415.

PMID:
18825658
36.

Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer.

Barber M, Murrell A, Ito Y, Maia AT, Hyland S, Oliveira C, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC.

J Pathol. 2008 Nov;216(3):295-306. doi: 10.1002/path.2426.

PMID:
18788075
37.

A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma.

Chang CL, Hong E, Lao-Sirieix P, Fitzgerald RC.

Oncogene. 2008 May 8;27(21):2951-60. Epub 2007 Dec 3.

PMID:
18059332
38.

Non-endoscopic immunocytological screening test for Barrett's oesophagus.

Lao-Sirieix P, Rous B, O'Donovan M, Hardwick RH, Debiram I, Fitzgerald RC.

Gut. 2007 Jul;56(7):1033-4. No abstract available.

39.
40.

Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance.

Lao-Sirieix P, Lovat L, Fitzgerald RC.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65.

41.

Retinoic acid-induced glandular differentiation of the oesophagus.

Chang CL, Lao-Sirieix P, Save V, De La Cueva Mendez G, Laskey R, Fitzgerald RC.

Gut. 2007 Jul;56(7):906-17. Epub 2006 Dec 21.

42.

Surveillance and screening of Barrett's oesophagus.

Lao-Sirieix P, Fitzgerald R.

Br J Hosp Med (Lond). 2006 Jul;67(7):355-9. Review. No abstract available.

PMID:
16884144
43.

Effect of acid suppression on molecular predictors for esophageal cancer.

Lao-Sirieix P, Roy A, Worrall C, Vowler SL, Gardiner S, Fitzgerald RC.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):288-93.

44.

Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation.

Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y, Lao-Sirieix P, Caldas C, Fitzgerald RC.

Gut. 2006 Jun;55(6):764-74. Epub 2005 Dec 20.

45.

Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis.

Lao-Sirieix P, Brais R, Lovat L, Coleman N, Fitzgerald RC.

Neoplasia. 2004 Nov-Dec;6(6):751-60.

46.

Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.

Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC.

Clin Cancer Res. 2004 Jul 15;10(14):4784-92.

47.

Barrett's oesophagus and adenocarcinoma.

Caygill CP, Watson A, Lao-Sirieix P, Fitzgerald RC.

World J Surg Oncol. 2004 May 7;2:12. No abstract available.

Supplemental Content

Loading ...
Support Center